Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CIFU vs CLSX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLSX Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 1–1 Matrix Metrics)

CLSX Overall Winner 6-Pillar Tally: CIFU 0 – 0 CLSX (6 Tie) Matrix Metrics: CIFU 1 – 1 CLSX

As of Nov 20, 2026, Tradr 2X Long CLSK Daily ETF (CLSX) is the stronger overall head-to-head candidate over CIFU (CIFU) in the Tradestie Institutional Equity Comparison Engine, winning 1–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). CIFU carries a Unified Composite Score of 42.0/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin), whereas CLSX carries 41.7/100 (SELL) at $1.36 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: CIFU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile CLSX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CIFU vs CLSX
CIFU US Equity
CIFU
Institutional Equity
$0.72
-33.71% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 7.28β · 314% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -42.1%), weak momentum, RSI 28
RSI-14: 28.4 · SMA20: $1.39 · SMA50: $5.02
CLSX Cboe BZX Head-to-Head Winner
Tradr 2X Long CLSK Daily ETF
Institutional Equity
$1.36
-33.41% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 6.83β · 264% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 25.0 Fund 56.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.3%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $3.12 · SMA50: $7.59

6-Pillar Scorecard Institutional Category Breakdown (CIFU 0 – 0 CLSX)

Columns: Metric · CIFU · CLSX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 188.6% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CIFU (1) vs CLSX (1)
Institutional Metric CIFU CLSX Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
0% ($1–$51) 0% ($1–$42) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
7.28β · 314% Vol 6.83β · 264% Vol Lower Realized Risk CLSX
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite CIFU
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CIFU +3.92 pp
CIFU: -67.16% · CLSX: -71.08%
3M Horizon CLSX +4.06 pp
CIFU: -92.25% · CLSX: -88.19%
6M Horizon CLSX +2.73 pp
CIFU: -97.61% · CLSX: -94.88%
1Y Horizon CLSX +5.07 pp
CIFU: -96.96% · CLSX: -91.89%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CIFU vs CLSX. Trailing 12-month operating profitability (CIFU N/A vs CLSX N/A) and valuation multiples (CIFU N/M vs CLSX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CIFU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CLSX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CIFU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CIFU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLSX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 188.6%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLSX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CIFU Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLSX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CIFU vs CLSX Key Questions & Quantitative Answers

As of Nov 20, 2026, Tradr 2X Long CLSK Daily ETF (CLSX) is the stronger overall head-to-head candidate over CIFU (CIFU) in the Tradestie Institutional Equity Comparison Engine, winning 1–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). CIFU carries a Unified Composite Score of 42.0/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin), whereas CLSX carries 41.7/100 (SELL) at $1.36 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: CIFU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile CLSX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CIFU and CLSX split Growth & Scale metrics: CIFU posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CLSX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CIFU generates N/A in USD-normalized revenue versus N/A for CLSX. In operating R&D and SG&A reinvestment, CIFU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLSX.

CIFU and CLSX trade at balanced relative valuation multiples. CIFU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CLSX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CIFU (N/A ROE) versus CLSX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, CIFU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (7.28β · 314% Vol realized risk). By comparison, CLSX carries 188.6% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.83β · 264% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.